Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
- 1 December 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 94 (6), 2493-2503
- https://doi.org/10.1172/jci117619
Abstract
Dysregulated extracellular matrix (ECM) metabolism may contribute to vascular remodeling during the development and complication of human atherosclerotic lesions. We investigated the expression of matrix metalloproteinases (MMPs), a family of enzymes that degrade ECM components in human atherosclerotic plaques (n = 30) and in uninvolved arterial specimens (n = 11). We studied members of all three MMP classes (interstitial collagenase, MMP-1; gelatinases, MMP-2 and MMP-9; and stromelysin, MMP-3) and their endogenous inhibitors (TIMPs 1 and 2) by immunocytochemistry, zymography, and immunoprecipitation. Normal arteries stained uniformly for 72-kD gelatinase and TIMPs. In contrast, plaques' shoulders and regions of foam cell accumulation displayed locally increased expression of 92-kD gelatinase, stromelysin, and interstitial collagenase. However, the mere presence of MMP does not establish their catalytic capacity, as the zymogens lack activity, and TIMPs may block activated MMPs. All plaque extracts contained activated forms of gelatinases determined zymographically and by degradation of 3H-collagen type IV. To test directly whether atheromata actually contain active matrix-degrading enzymes in situ, we devised a method which allows the detection and microscopic localization of MMP enzymatic activity directly in tissue sections. In situ zymography revealed gelatinolytic and caseinolytic activity in frozen sections of atherosclerotic but not of uninvolved arterial tissues. The MMP inhibitors, EDTA and 1,10-phenanthroline, as well as recombinant TIMP-1, reduced these activities which colocalized with regions of increased immunoreactive MMP expression, i.e., the shoulders, core, and microvasculature of the plaques. Focal overexpression of activated MMP may promote destabilization and complication of atherosclerotic plaques and provide novel targets for therapeutic intervention.This publication has 28 references indexed in Scilit:
- Inhibition of Matrix Metalloproteinase 9 Activation by a Specific Monoclonal AntibodyHybridoma, 1993
- Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.Heart, 1993
- The matrix‐degrading metalloproteinasesBioEssays, 1992
- Detection of Stromelysin and Collagenase in Synovial Fluid From Patients with Rheumatoid Arthritis and Posttraumatic Knee InjuryArthritis & Rheumatism, 1992
- Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factorAtherosclerosis, 1991
- Detection and localization of tumor necrosis factor in human atheromaThe American Journal of Cardiology, 1990
- Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysinFEBS Letters, 1988
- Compensatory Enlargement of Human Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1987
- Inducible interleukin-1 gene expression in human vascular smooth muscle cells.Journal of Clinical Investigation, 1986
- Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.Journal of Clinical Investigation, 1986